Relationships Between Authors of Clinical Practice Guidelines and the Pharmaceutical Industry | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.108.182. Please contact the publisher to request reinstatement.
[Skip to Navigation Landing]
1.
Boyd EA, Bero LA. Assessing faculty financial relationships with industry.  JAMA.2000;284:2209-2214.Google Scholar
2.
Chren M, Landefeld C. Physicians' behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary.  JAMA.1994;271:684-689.Google Scholar
3.
Caudill TS, Johnson MS, Rich EC, McKinney WP. Physicians, pharmaceutical sales representatives and the cost of prescribing.  Arch Fam Med.1996;5:201-206.Google Scholar
4.
Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives.  JAMA.1995;273:1296-1298.Google Scholar
5.
Sandberg WS, Carlos R, Sandberg EH, Roizen MF. The effect of educational gifts from pharmaceutical firms on medical students' recall of company names of products.  Acad Med.1997;72:916-918.Google Scholar
6.
Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift?  JAMA.2000;283:373-380.Google Scholar
7.
Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists.  N Engl J Med.1998;338:101-106.Google Scholar
8.
Davidson RA. Source of funding and outcome of clinical trials.  J Gen Intern Med.1986;1:155-158.Google Scholar
9.
Rochon PA, Gurwitz JH, Simms RW.  et al.  A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis.  Arch Intern Med.1994;154:157-163.Google Scholar
10.
Friedberg M, Saffran B, Stinson TJ, Nelson W, Benett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology.  JAMA.1999;282:1453-1457.Google Scholar
11.
 Practice parameters for the diagnosis and treatment of asthma.  J Allergy Clin Immunol.1995;96:707-870.Google Scholar
12.
 Guidelines for the diagnosis and management of asthma.  J Allergy Clin Immunol.1991;88:425-534.Google Scholar
13.
 Guidelines on the management of asthma.  Thorax.1993;48:S1-S24.Google Scholar
14.
Beveridge RC, Grunfeld AF, Hoder RV, Verbeek PR. Guidelines for the emergency management of asthma in adults.  CMAJ.1996;155:25-37.Google Scholar
15.
North of England Asthma Guideline Development Group.  North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management of asthma in adults.  BMJ.1996;312:762-766.Google Scholar
16.
Canadian Thoracic Society Workshop Group.  Guidelines for the assessment and management of chronic obstructive pulmonary disease.  CMAJ.1992;147:420-428.Google Scholar
17.
Hochberg MC, Altman RD, Brandt KD.  et al.  Guidelines for the medical management of osteoarthritis.  Arthritis Rheum.1995;38:1535-1540.Google Scholar
18.
Holbrook AM, Sabharwal M, Trepanier EF. Medical Treatment Guidelines for the Treatment of Osteoarthritis, Rheumatoid Arthritis, and Acute Musculoskeletal InjuryToronto: Queen's Printer for Ontario; 1999.
19.
American Psychiatric Association.  Practice guideline for major depressive disorder in adults.  Am J Psychiatry.1993;150(4 Suppl):1-26.Google Scholar
20.
British Diabetic Association, Royal College of Physicians, and Royal College of General Practitioners.  Guidelines for good practice in the diagnosis and treatment of non-insulin-dependent diabetes mellitus.  J R Coll Physicians Lond.1993;27:259-266.Google Scholar
21.
Expert Committee of the Canadian Diabetes Advisory Board.  Clinical practice guidelines for treatment of diabetes mellitus.  CMAJ.1992;147:697-712.Google Scholar
22.
Meltzer S, Leiter L, Daneman D.  et al.  1998 Clinical practice guidelines for the management of diabetes in Canada.  CMAJ.1998;159:S1-S29.Google Scholar
23.
European IDDM Policy Group 1993.  Consensus guidelines for the management of insulin-dependent (type 1) diabetes.  Diabet Med.1993;10:990-1005.Google Scholar
24.
 AACE guidelines for the management of diabetes mellitus.  Endocr Pract.1995;1:149-157.Google Scholar
25.
Soll AH.for the Practice Parameters Committee of the American College of Gastroenterology.  Medical treatment of peptic ulcer disease.  JAMA.1996;275:622-629.Google Scholar
26.
DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease.  Arch Intern Med.1995;155:2165-2173.Google Scholar
27.
Hunt R, Thomson ABR. Canadian Helicobacter pylori consensus conference.  Can J Gastroenterol.1998;12:31-41.Google Scholar
28.
Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee.  Summary of the 1993 World Health Organization–International Society of Hypertension guidelines for the management of mild hypertension.  BMJ.1993;307:1541-1546.Google Scholar
29.
Sever P, Beevers G, Bulpitt C.  et al.  Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society.  BMJ.1993;306:983-987.Google Scholar
30.
Myers MG, Gryfe CI, Leenen FH, Haynes RB, Ogilvie RI. Guidelines for the Treatment of Uncomplicated Hypertension.  Toronto: Queen's Printer for Ontario; 1995.
31.
Ogilvie RI, Burgess ED, Cusson JR, Feldman RD, Leiter LA, Myers MG. Report of the Canadian Hypertensive Society Consensus Conference.  CMAJ.1993;149:575-584.Google Scholar
32.
Evans CE. Canadian Consensus Conference on Hypertension Management, 1984-1992Montreal, Quebec: Canadian Hypertension Society; 1993.
33.
 Sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.  Arch Intern Med.1997;157:2413-2446.Google Scholar
34.
Betteridge DJ, Dodson PM, Durrington PN.  et al.  Management of hyperlipidemia: guidelines of the British Hyperlipidemia Association.  Postgrad Med J.1993;69:359-369.Google Scholar
35.
Frohlich J, Fodor G, McPherson R, Genest J, Langner N. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report.  Can J Cardiol.1998;14(suppl A):17A-21A.Google Scholar
36.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).  JAMA.1993;269:3015-3023.Google Scholar
37.
 ASHP therapeutic guidelines on angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction.  Am J Health Syst Pharm.1997;54:299-313.Google Scholar
38.
ACC/AHA Task Force.  Guidelines for the evaluation and management of heart failure.  Circulation.1995;92:2764-2784.Google Scholar
39.
Johnstone DE, Abdulla A, Arnold JM.  et al.  Diagnosis and management of heart failure.  Can J Cardiol.1994;10:613-631.Google Scholar
40.
Agency for Health Care Policy and Research.  Heart Failure: Evaluation and Care of Patients With Left-Ventricular Systolic Dysfunction. Rockville, Md: US Dept of Health and Human Services; June 1994.
41.
Ontario Anti-infective Review Panel.  Anti-infective guidelines for community-acquired infections. 2nd ed. Toronto: Queen's Printer for Ontario; 1997.
42.
The British Thoracic Society.  Guidelines for the management of community-acquired pneumonia in adults admitted to hospital.  Br J Hosp Med.1993;49:346-350.Google Scholar
43.
American Thoracic Society.  Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies.  Am J Respir Crit Care Med.1996;153:1711-1725.Google Scholar
44.
European Study on Community-Acquired Pneumonia Committee.  Guidelines for management of adult community-acquired lower respiratory tract infections.  Eur Respir J.1998;11:986-991.Google Scholar
45.
American Thoracic Society.  Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy.  Am Rev Respir Dis.1993;148:1418-1426.Google Scholar
46.
Mandell LA, Marrie TJ, Niederman MS. Initial antimicrobial treatment of hospital acquired pneumonia in adults.  Can J Infect Dis.1993;4:317-321.Google Scholar
47.
Mandell LA, Niederman MS. Antimicrobial treatment of community acquired pneumonia in adults.  Can J Infect Dis.1993;4:25-28.Google Scholar
48.
Bartlett JG, Breiman RF, Mandell LA, File TM. Community-acquired pneumonia in adults: guidelines for management.  Clin Infect Dis.1998;26:811-838.Google Scholar
49.
Ryan TJ, Anderson JL, Antman EM.  et al.  ACC/AHA guidelines for the management of patients with acute myocardial infarction.  Circulation.1996;94:2341-2350.Google Scholar
50.
Weston CF, Penny WJ, Julian DG. Guidelines for the early management of patients with myocardial infarction.  BMJ.1994;308:767-771.Google Scholar
51.
North of England Stable Angina Guideline Development Group.  North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management of stable angina.  BMJ.1996;312:827-832.Google Scholar
52.
Gibbons RJ, Chatterjee K, Daley J.  et al.  ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina.  J Am Coll Cardiol.1999;33:2092-2197.Google Scholar
53.
De Bono DP, Hopkins A. The management of acute myocardial infarction: guidelines and audit standards.  J R Coll Physicians Lond.1994;28:312-317.Google Scholar
54.
Agency for Health Care Policy and Research.  Unstable Angina: Diagnosis and Management.  Rockville, Md: US Dept of Health and Human Services; 1994.
55.
The COPD Guidelines Group of the Standards of Care Committee of the BTS.  BTS Guidelines for the management of chronic obstructive pulmonary disease.  Thorax.1997;52:S1-S28.Google Scholar
56.
Fein AM, Niederman MS. Guidelines for the initial management of community-acquired pneumonia: savory recipe or cookbook for disaster?  Am J Respir Crit Care Med.1995;152:1149-1153.Google Scholar
57.
Gleason PP, Kapoor WN, Stone RA.  et al.  Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia.  JAMA.1997;278:32-39.Google Scholar
58.
Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach: a randomized controlled trial of academically based "detailing."  N Engl J Med.1983;308:1457-1463.Google Scholar
Original Contribution
February 6, 2002

Relationships Between Authors of Clinical Practice Guidelines and the Pharmaceutical Industry

Author Affiliations

Author Affiliations: Departments of Medicine (Drs Choudhry, Stelfox, and Detsky) and Health Policy, Management and Evaluation (Dr Detsky), University of Toronto, and Department of Medicine, University Health Network and Mount Sinai Hospital (Drs Choudhry and Detsky), Toronto, Ontario; and the PhD Program in Health Care Policy, Harvard University, Boston, Mass (Drs Choudhry and Stelfox).

JAMA. 2002;287(5):612-617. doi:10.1001/jama.287.5.612
Abstract

Context Increasing contact has been reported between physicians and the pharmaceutical industry, although no data exist in the literature regarding potential financial conflicts of interest for authors of clinical practice guidelines (CPGs). These interactions may be particularly relevant since CPGs are designed to influence the practice of a large number of physicians.

Objective To quantify the extent and nature of interactions between authors of CPGs and the pharmaceutical industry.

Design, Setting, and Participants Cross-sectional survey of 192 authors of 44 CPGs endorsed by North American and European societies on common adult diseases published between 1991 and July 1999. One hundred authors (52%) provided usable responses representing 37 of 44 different CPGs that we identified.

Main Outcome Measures Nature and extent of interactions of authors with drug manufacturers; disclosure of relationships in published guidelines; prior discussion among authors regarding relationships; beliefs regarding whether authors' own relationships or those of their colleagues influenced treatment recommendations in guidelines.

Results Eighty-seven percent of authors had some form of interaction with the pharmaceutical industry. Fifty-eight percent had received financial support to perform research and 38% had served as employees or consultants for a pharmaceutical company. On average, CPG authors interacted with 10.5 different companies. Overall, an average of 81% (95% confidence interval, 70%-92%) of authors per CPG had interactions. Similarly, all of the CPGs for 7 of the 10 diseases included in our study had at least 1 author who had some interaction. Fifty-nine percent had relationships with companies whose drugs were considered in the guideline they authored, and of these authors, 96% had relationships that predated the guideline creation process. Fifty-five percent of respondents indicated that the guideline process with which they were involved had no formal process for declaring these relationships. In published versions of the CPGs, specific declarations regarding the personal financial interactions of individual authors with the pharmaceutical industry were made in only 2 cases. Seven percent thought that their own relationships with the pharmaceutical industry influenced the recommendations and 19% thought that their coauthors' recommendations were influenced by their relationships.

Conclusions Although the response rate for this survey was low, there appears to be considerable interaction between CPG authors and the pharmaceutical industry. Our study highlights the need for appropriate disclosure of financial conflicts of interest for authors of CPGs and a formal process for discussing these conflicts prior to CPG development.

×